{"groups":[{"description":"Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.","id":"FG000","title":"Placebo"},{"description":"Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.","id":"FG001","title":"Mirabegron 50 mg"},{"description":"Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.","id":"FG002","title":"Mirabegron 100 mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"}],"type":"Non-compliant with study procedures"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"65"},{"groupId":"FG001","numSubjects":"70"},{"groupId":"FG002","numSubjects":"65"}],"type":"STARTED"},{"achievements":[{"comment":"All patients who received at least 1 dose of double-blind study drug.","groupId":"FG000","numSubjects":"65"},{"comment":"All patients who received at least 1 dose of double-blind study drug.","groupId":"FG001","numSubjects":"70"},{"comment":"All patients who received at least 1 dose of double-blind study drug.","groupId":"FG002","numSubjects":"65"}],"type":"Safety Analysis Set (SAF)"},{"achievements":[{"comment":"SAF patients with both Qmax \\& PdetQmax measurements at baseline and 1 or both measured postbaseline.","groupId":"FG000","numSubjects":"63"},{"comment":"SAF patients with both Qmax \\& PdetQmax measurements at baseline and 1 or both measured postbaseline.","groupId":"FG001","numSubjects":"64"},{"comment":"SAF patients with both Qmax \\& PdetQmax measurements at baseline and 1 or both measured postbaseline.","groupId":"FG002","numSubjects":"58"}],"type":"Full Analysis Set (FAS)"},{"achievements":[{"groupId":"FG000","numSubjects":"63"},{"groupId":"FG001","numSubjects":"67"},{"groupId":"FG002","numSubjects":"58"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"7"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}